Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Kansai Myeloma Forum Investigators"'
Autor:
Itaru Matsumura, Junya Kuroda, Junya Kanda, Shosaku Nomura, Yuji Shimura, Nobuhiko Uoshima, Jun Ishikawa, Katsuya Wada, Masayuki Hino, Yuzuru Kanakura, Yutaka Shimazu, Hitomi Kaneko, Akifumi Takaori-Kondo, Kansai Myeloma Forum Investigators, Tomoki Ito, Chihiro Shimazaki, Yoshiyuki Onda, Satoru Kosugi, Toru Kida, Ryosuke Yamamura, Shin-ichi Fuchida, Hirohiko Shibayama, Takae Kohara, Satoshi Yoshihara, Aya Nakaya, Miki Kiyota, Hideo Yagi, Kensuke Ohta, Kazunori Imada, Hirokazu Tanaka
Publikováno v:
International Journal of Hematology. 112:435-438
We retrospectively analyzed the clinical features and outcomes in a real-world cohort of adolescents and the young adult (AYA) patients (age between 16 and 39 years) with symptomatic multiple myeloma (MM) registered with the Kansai Myeloma Forum. 26
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50c49f3efca089c372ecde178c5e6fcd
https://doi.org/10.1007/s12185-020-02996-6
https://doi.org/10.1007/s12185-020-02996-6
Autor:
Toru Kida, Hitomi Kaneko, Toshimitsu Matsui, Miki Kiyota, Shin-ichi Fuchida, Shosaku Nomura, Takae Kohara, Kansai Myeloma Forum Investigators, Nobuhiko Uoshima, Ryoichi Takahashi, Yoko Adachi, Kazunori Imada, Kensuke Ohta, Satoru Kosugi, Hirokazu Tanaka, Mitsuhiro Matsuda, Masato Iida, Akifumi Takaori-Kondo, Junya Kanda, Hideo Yagi, Hitoji Uchiyama, Masayuki Hino, Hirohiko Shibayama, Yuji Shimura, Yuzuru Kanakura, Katsuya Wada, Junya Kuroda, Takahiro Karasuno, Aya Nakaya, Itaru Matsumura, Maki Shindo, Chihiro Shimazaki
Publikováno v:
International Journal of Hematology. 112:666-673
We retrospectively analyzed 51 patients with solitary plasmacytoma diagnosed from October 2002 to September 2018 from a cohort of 3575 patients with plasma cell dyscrasias registered in the Kansai Myeloma Forum. Twenty-seven patients had solitary bon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09e23912ba2625709c582de2d7e570ac
https://doi.org/10.1007/s12185-020-02961-3
https://doi.org/10.1007/s12185-020-02961-3
Autor:
Masayuki Kobayashi, Junya Kuroda, Toru Kida, Yuri Kamitsuji, Shin-ichi Fuchida, Takayuki Takahashi, Yoko Adachi, Hitomi Kaneko, Satoru Kosugi, Kazue Miyamoto, Tsuneyoshi Hamada, Itaru Matsumura, Hirokazu Tanaka, Chihiro Shimazaki, Akifumi Takaoari-Kondo, Hitoji Uchiyama, Hirohiko Shibayama, Kensuke Ohta, Shosaku Nomura, Hideo Yagi, Aya Nakaya, Takae Kohara, Eri Kawata, Yuji Shimura, Yuzuru Kanakura, Masayuki Hino, Fumiaki Urase, Nobuhiko Uoshima, Kansai Myeloma Forum Investigators, Maki Shindo
Publikováno v:
Leukemia Research Reports, Vol 10, Iss, Pp 7-10 (2018)
Leukemia Research Reports
Leukemia Research Reports
Highlights • The prevalence of pPCL was 1.2%. • Treatment with novel agents and transplantation may yield a better prognosis. • Hypercalcemia at diagnosis was suggested to predict worse outcomes.
We retrospectively analyzed twenty-six pati
We retrospectively analyzed twenty-six pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ba0d9bbca03060060c40221780d0d62
http://www.sciencedirect.com/science/article/pii/S2213048918300438
http://www.sciencedirect.com/science/article/pii/S2213048918300438
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Katsuya Wada, Masayuki Hino, Hitomi Kaneko, Masayuki Kobayashi, Toshimitsu Matsui, Isao Yokota, Aya Nakaya, Hirokazu Tanaka, Nobuhiko Uoshima, Mitsuhiro Matsuda, Satoru Kosugi, Shin-ichi Fuchida, Kazunori Imada, Masato Iida, Yayoi Matsumura-Kimoto, Yuri Kamitsuji, Hideo Yagi, Hirohiko Shibayama, Shosaku Nomura, Chihiro Shimazaki, Hitoji Uchiyama, Akifumi Takaori-Kondo, Itaru Matsumura, Kansai Myeloma Forum Investigators, Kensuke Ohta, Yuzuru Kanakura, Junya Kuroda, Jun Ishikawa
Publikováno v:
International journal of hematology. 107(5)
Determinants of the efficacy and safety of pomalidomide (POM) monotherapy or POM plus dexamethasone (DEX) (POM/DEX) for relapsed and refractory multiple myeloma (RRMM) were examined retrospectively in a real-world clinical practice setting in Japan.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c14dbaf73b50f6e2d7b15023efebb045
https://pubmed.ncbi.nlm.nih.gov/29380179
https://pubmed.ncbi.nlm.nih.gov/29380179
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Chihiro Shimazaki, Hirokazu Tanaka, Junya Kuroda, Kensuke Ohta, Mitsuru Tsudo, Yuzuru Kanakura, Nobuhiko Uoshima, Hitomi Kaneko, Shin-ichi Fuchida, Masayuki Kobayashi, Hirohiko Shibayama, Satoru Kosugi, Shosaku Nomura, Masafumi Taniwaki, Kazuyoshi Ishii, Masayuki Hino, Akifumi Takaori-Kondo, Itaru Matsumura, Kansai Myeloma Forum Investigators, Yuji Shimura
Publikováno v:
International journal of hematology. 99(4)
We retrospectively investigated clinical outcomes and prognostic factors of 131 patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) who received melphalan and prednisolone (MP) as first-line therapy from 2006 to 2013. Eighty-o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1fafedd75bd6d46d4e54efcc151daf2
https://pubmed.ncbi.nlm.nih.gov/24584872
https://pubmed.ncbi.nlm.nih.gov/24584872